Trials / Completed
CompletedNCT00685061
Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation
Head-to-Head Comparison of Thymoglobulin vs. Campath-1H vs. Our Standard Center Treatment Protocol in Cadaver Donor Renal Transplantation: A Study to Evaluate the Avoidance of Long-Term Nephrotoxic Calcineurin Inhibitor Therapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- University of Miami · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
To compare in a randomized prospective study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy vs. our conventional therapy in recipients of first cadaver (CAD) kidneys.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thymoglobulin | Induction |
| DRUG | Campath-1H | Induction |
| DRUG | Daclizumab | Induction |
Timeline
- Start date
- 2002-11-01
- Primary completion
- 2004-09-01
- Completion
- 2005-09-01
- First posted
- 2008-05-28
- Last updated
- 2023-10-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00685061. Inclusion in this directory is not an endorsement.